Categorized | Prostate Treatment

Investigational Drug Cabozantinib Active Against Advanced Prostate Cancer

When prostate cancer stops responding to androgen deprivation therapy (ADT), it is referred to as hormone-refractory prostate cancer. Although advances have been made in the treatment of hormone-refractory prostate cancer, challenges remain and new drugs continue to be developed.

An investigational drug called Cabozantinib is showing promise in the treatment of hormone-refractory prostate cancer particularly among patients with bone metastases.

Researchers conducted a Phase II clinical trial among 171 patients with progressive cancer in which more than three-quarters of the men had bone metastases. All patients were initially treated with 12 weeks of Cabozantinib. On bone scan, 76% of the patients with bone metastases had partial or complete disappearance of the bone metastases. For patients taking narcotics for bone pain, 67% had a reduction in pain and 56% decreased or stopped their narcotic use. More than two thirds of patients had some reduction in metastases outside of the bone.

Side effects include fatigue, gastrointestinal symptoms and high blood pressure.

These results were presented at the 2011 annual meeting of the American Society of Clinical Oncology.

Additional studies are underway.

Cabozantinib has not yet been approved by the U.S. Food and Drug Administration.

3 Responses to “Investigational Drug Cabozantinib Active Against Advanced Prostate Cancer”

  1. Benton Vorce says:

    Excellent article. Thanks for the information. I know it will help.

  2. This is good. I know it will help me personally in what I’m doing. I’m going to share this with my friends.

  3. I was very pleased to locate this web-site.I wanted to interesting time with this fantastic study!! I certainly taking pleasure in each and every bit of it and I have you bookmarked to check out brand new items you article.



June 2011
« May   Jul »